Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2021 | Cluster headache: unmet needs in a disabling condition

Rigmor Hojland Jensen • 11 Jun 2021
EAN 2021
Headache

Rigmor Jensen, MD, University of Copenhagen, Glostrup, Denmark, outlines the major unmet needs in the field of cluster headache. Firstly, increased awareness and education among clinicians and the general population is crucial to tackle the high rate of misdiagnosis currently seen. Prof. Jensen also highlights the need for new treatments that can abort a cluster bout and are well tolerated. This interview took place during the European Academy of Neurology 2021 congress.

More from Rigmor Hojland Jensen

Recognizing medication overuse headache and optimizing underlying headache management
4:00
Recognizing medication overuse headache and optimizing underlying headache management
Rigmor Hojland Jensen • 28 Jun 2026
Spontaneous intracranial hypotension: insights from a session at EAN 2026
4:31
Spontaneous intracranial hypotension: insights from a session at EAN 2026
Rigmor Hojland Jensen • 28 Jun 2026
Diagnosing idiopathic intracranial hypertension: blood versus CSF
4:03
Diagnosing idiopathic intracranial hypertension: blood versus CSF
Rigmor Hojland Jensen • 23 Jun 2025
The effectiveness of eptinezumab in chronic migraine and medication-overuse headache: RESOLUTION
4:43
The effectiveness of eptinezumab in chronic migraine and medication-overuse headache: RESOLUTION
Rigmor Hojland Jensen • 23 Jun 2025

Related Videos

TRIPLE study: triple combination therapy for chronic migraine
2:41
TRIPLE study: triple combination therapy for chronic migraine
Marina Romozzi • 27 Jun 2026
PACAP-38 is increased in the tear fluid of patients with migraine
1:50
PACAP-38 is increased in the tear fluid of patients with migraine
Marina Romozzi • 27 Jun 2026
Combination therapy for migraine: anti-CGRP, anti-PACAP, and onabotulinumtoxinA
8:49
Combination therapy for migraine: anti-CGRP, anti-PACAP, and onabotulinumtoxinA
Richard Lipton • 1 Jul 2026
CONFIDENCE: real-world consistency of response to rimegepant for the acute treatment of migraine
5:05
CONFIDENCE: real-world consistency of response to rimegepant for the acute treatment of migraine
Richard Lipton • 1 Jul 2026

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJNeurology is intended for healthcare professionals